AnaptysBio, Inc. research snapshot
ANAB AI stock analysis currently reads AnaptysBio as a clinical-stage immunology biotechnology company with a differentiated pipeline led by rosnilimab (anti-PD-1 agonist for rheumatoid arthritis, Phase 2b complete), imsidolimab (anti-IL-36R for generalized pustular psoriasis, Phase 3), ANB033 (anti-CD122 for celiac disease and eosinophilic esophagitis, Phase 1b), and ANB101 (anti-BDCA2, Phase 1a). For the trailing twelve months ended March 2026, AnaptysBio reported total revenue of about $232 million, net loss of about $27 million, and EPS of -$1.02. Cash plus equivalents were about $286 million, and the company carries minimal debt. At the July 12, 2026 intraday reference of $67.92 and about 29.6 million shares outstanding, the verified market cap was about $2.01 billion. This ANAB AI stock forecast is scenario-based, not a precise price prediction, and should be used as an informational research tool, not investment advice.
Current price
$67.92 intraday reference on July 12, 2026
Market cap
$2.01 billion equity value
AI score
52 / 100
Rating
Clinical-stage immunology biotech with collaboration revenue, a potentially transformative rosnilimab RA program, imsidolimab GPP Phase 3 catalyst, and significant binary pipeline risk
Trend status
Strong uptrend with 334% one-year return; stock near 52-week highs of $72.36 and showing momentum from recent pipeline updates
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | AnaptysBio monetizes antibody discovery and immunology pipeline development through research collaborations and, if approved, future product sales. The current business is pre-commercial with episodic collaboration revenue. | Low-medium |
| Moat | The moat comes from proprietary antibody discovery technology, PD-1 agonist biology expertise, IL-36R targeting, IP and patents. It narrows if competitors develop better or faster programs, partner priorities shift, or clinical data disappoints. | Low |
| Management | CEO Daniel Faga has refocused the pipeline around immunology, progressed rosnilimab through Phase 2b, and added new early-stage programs. The recent CFO appointment and Board addition suggest governance improvements. | Medium-low |
| Financial trend | TTM revenue of about $232 million was driven by collaboration income. TTM net loss of $27 million and negative EPS of -$1.02 show the company is still unprofitable on GAAP basis. Cash of $286 million provides runway but limits the margin for error. | Medium |
| Valuation | At $67.92, ANAB trades at about 7.7x TTM sales and has negative P/E because of GAAP losses. EV/Revenue of about 6.9x. The valuation reflects pipeline potential rather than current earnings power. | Medium |
| Technical trend | The stock has been in a strong uptrend from the $11.40 52-week low to near $72.36 highs. Momentum indicators suggest the stock is extended but still in a bullish trend channel. Volume picks up on pipeline news. | Medium |
| Risk level | Very high. Key risks are clinical trial failure, regulatory setbacks, partnership-dependent revenue, cash burn and potential dilution, low institutional coverage, and extreme stock volatility common in small-cap biotech. | Medium |
| AI confidence | Descriptive data confidence is medium because key data points (market cap, cash, revenue) were verified from Yahoo Finance, but FDA calendars, partnership negotiations, and clinical outcomes are not publicly predictable. | Medium data confidence |
| Investment certainty | ANAB has shown impressive stock momentum and the rosnilimab and imsidolimab programs have real potential, but the risk-reward is heavily weighted toward binary clinical outcomes that make investment certainty low. | Low |
ANAB AI stock forecast
The ANAB AI stock forecast uses the July 12, 2026 intraday reference of $67.92, TTM revenue of about $232 million, TTM loss per share of -$1.02, and a revenue-based scenario framework. Because EPS is negative, the model uses a price-to-sales range anchored to the current 7.7x P/S. The bearish area assumes pipeline setbacks, the base case reflects gradual approval and revenue growth, and the bullish case assumes successful Phase 3 data and commercial launch. These are scenario ranges, not promises.
$100 to $125
More likely if rosnilimab shows strong Phase 2b efficacy data and advances to Phase 3, imsidolimab wins GPP approval, the pipeline generates new collaboration revenue, and the market re-rates ANAB toward a 10-12x sales multiple reflecting commercial potential.
$60 to $85
More likely if rosnilimab progresses steadily, imsidolimab shows reasonable Phase 3 data, collaboration revenue sustains near current levels, and ANAB trades near 6-8x forward sales, consistent with the current valuation range.
$25 to $45
More likely if rosnilimab Phase 2b data disappoints, imsidolimab hits regulatory delays, partnerships are not renewed or expanded, cash burn accelerates requiring dilutive financing, or the biotech sector sentiment weakens.
ANAB AI technical analysis
ANAB AI technical analysis shows a powerful uptrend that has carried the stock from $11.40 to $72.36 over the past 52 weeks. As of the July 13, 2026 data cutoff, the stock is trading near $67.92, just below its 52-week high. The stock has low beta (0.38) in absolute terms but high event-driven volatility on clinical and partnership news.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $67.92 | July 12, 2026 intraday reference from Yahoo Finance. Stock was up 9.00% on the day. |
| All-time / 52-week high | $72.36 | The 52-week high represents the upper end of the current trading range and a potential resistance level. |
| Near support | $60 to $62 | The previous close of $62.31 and round-number $60 support form the first pullback zone. |
| Secondary support | $48 to $50 | The bid-side liquidity around $48-50 and the round-number $50 level mark deeper support. |
| Deep support | $35 to $40 | Pre-surge consolidation levels and the gap-fill area below the major uptrend. |
| Near resistance | $68 to $73 | The 52-week high of $72.36 and the round-number $70-73 zone form the immediate resistance band. |
| Upper resistance | $80 to $90 | Analyst consensus target of $87.09 and the $80-90 round-number zone represent the next leg higher if the uptrend continues. |
| Moving averages | No reliable MA data from single source | Given the volatile and news-driven nature of the stock, moving averages may be less reliable than support/resistance levels. |
| Momentum | Strong positive, RSI potentially elevated | With a 334% one-year return and 9% single-day gain, momentum is strong but the stock may be technically extended. |
| Volume | Average near 676K shares | Volume often spikes on clinical data releases and partnership announcements. 788K shares traded on the reference day. |
| Volatility | Beta of 0.38, event volatility very high | Low statistical beta masks the binary-event risk. Clinical data days, FDA decisions, and partnership news can move the stock 20-50% in either direction. |
| Invalidation | Close below $50, then below $35 | A close below $50 would break the major uptrend support. A close below $35 would suggest the uptrend has fully reversed. |
ANAB AI trading strategy
The ANAB AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with pipeline catalysts, collaboration revenue sustainability, cash runway, dilution risk, and sector sentiment.
Track key catalysts: rosnilimab Phase 2b data release, imsidolimab Phase 3 progress, partnership announcements, quarterly earnings, and cash runway updates. A position held through binary events requires defined loss tolerance.
Clinical-stage biotech requires position sizes that reflect the possibility of 30-50% drawdowns on negative data. Do not risk capital that cannot afford binary outcomes.
If ANAB holds above $60-62 support and reclaims toward $72+ on above-average volume with constructive pipeline news, the primary uptrend remains intact.
A close below $60 support should trigger a review. A close below $50 would suggest the trend has broken and setup confidence should be reduced.
Monitor TTM collaboration revenue trajectory, quarterly cash burn, rosnilimab and imsidolimab clinical timelines, partnership developments, GAAP net income trend, and share count (dilution from equity offerings).
Position sizing should be conservative for a clinical-stage biotech. The stock can gap 30% or more on a single data release, making position sizing more important than entry price.
Investment research summary
AnaptysBio discovers and develops antibody-based immunology therapies. Customers (patients and payers) do not currently pay for products, but collaboration partners (GSK, Vanda) fund pipeline development through research payments and potential milestones.
The moat is anchored by proprietary antibody discovery platforms, deep PD-1 agonist biology expertise, IL-36R targeting, immunology patents, and early pipeline positions in celiac disease, eosinophilic esophagitis, and pDC modulation. It is narrow and unproven until products are approved and commercialized.
The thesis fails if rosnilimab underperforms in the Phase 2b-to-3 transition, imsidolimab hits regulatory or clinical hurdles, collaboration partners withdraw, the company needs dilutive financing, or the market reprices small-cap biotech risk downward.
CEO Daniel Faga has sharpened the immunology focus and advanced key pipeline assets. The recent CFO and Board appointments signal governance maturation. The next test is whether the pipeline can convert promising early data into approvable products and partnership renewals.
Immunology is one of biotech's most active therapeutic areas, with expanding targets, patient populations, and pricing power. The counter-trends are increasing competition in autoimmune disease, payer pushback on high drug prices, FDA caution on new mechanisms, and rising clinical trial costs.
ANAB is valued as a pre-commercial pipeline story at about 7.7x TTM sales and negative P/E. There is no traditional margin of safety based on earnings. The price already reflects positive expectations for the pipeline, meaning disappointments could produce significant downside.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $67.92 intraday on July 12, 2026 | Yahoo Finance ANAB summary | July 13, 2026 |
| Market capitalization | $2.01B, verified as $67.92 x 29.61M shares | financial_rigor.py market cap verification | July 13, 2026 |
| TTM revenue | $232.39M (trailing twelve months) | Yahoo Finance statistics | July 13, 2026 |
| TTM net income | -$26.79M, EPS -$1.02 | Yahoo Finance statistics | July 13, 2026 |
| Cash and equivalents | $286.46M (most recent quarter) | Yahoo Finance balance sheet | July 13, 2026 |
| Enterprise value | About $1.60B | Yahoo Finance statistics | July 13, 2026 |
| 52-week range | $11.40 to $72.36 | Yahoo Finance summary | July 13, 2026 |
| Beta (5Y monthly) | 0.38 | Yahoo Finance summary | July 13, 2026 |
| Price/Sales (TTM) | 7.71x | Yahoo Finance statistics | July 13, 2026 |
| EV/Revenue | 6.91x | Yahoo Finance statistics | July 13, 2026 |
| Analyst consensus target | $87.09 average, $140 high | Yahoo Finance analyst estimates | July 13, 2026 |
| Q4 FY25 revenue snapshot | $108.25M quarterly revenue, $49.61M quarterly earnings | Yahoo Finance earnings trends | July 13, 2026 |
This ANAB AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 13, 2026 and may be wrong if clinical data, FDA decisions, partnership terms, cash position, financing conditions, or market sentiment changes.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
